title: Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.
abstract: Recombinant human deoxyribonuclease (rhDNase) has been demonstrated to reduce the viscosity of purulent cystic fibrosis (CF) respiratory mucus, to improve pulmonary function and to reduce the risk of respiratory tract infectious exacerbations, but its effect on mucus transportability has not so far been investigated. The dose-dependent effect of rhDNase was analysed in vitro on mucus transport rate (tr) by ciliary activity and by simulated cough (cough transport (ct)), as well as on mucus viscosity and surface properties. Purulent CF sputa (n = 15) were incubated for 30 min at 37 degrees C with either rhDNase at three different concentrations (final concentrations 0.2, 2 or 20 micrograms.ml-1 of mucus) or placebo. No significant dose-dependent effect of rhDNase on the mucociliary transport rate was observed when the samples wer statistically analysed together. However, in the larger group of mucus samples (n = 11) with a low initial mucociliary transport rate, the latter was improved at each rhDNase concentration (tr0.2 = 0.69, tr2 = 0.88 and tr20 = 0.87) as compared to placebo (trp = 0.58). In the smaller group of mucus samples (n = 4) with high initial transport rate, a decrease in mucociliary transport rate was observed, particularly at the highest concentration rhDNase assayed, i.e. 20 micrograms.ml-1 of mucus (tr20 = 0.58) as compared to placebo (trp = 0.86). The mucus cough transport was increased by rhDNase (ct0.2 = 25 mm, ct2 = 27.5 mm and ct20 = 31 mm) as compared to placebo (ctp = 23.5 mm).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Inserm U314, Reims, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Zahm
authors.forename: S
authors.initials: S
authors.lastname: Girod de Bentzmann
authors.forename: E
authors.initials: E
authors.lastname: Deneuville
authors.forename: C
authors.initials: C
authors.lastname: Perrot-Minnot
authors.forename: A
authors.initials: A
authors.lastname: Dabadie
authors.forename: F
authors.initials: F
authors.lastname: Pennaforte
authors.forename: M
authors.initials: M
authors.lastname: Roussey
authors.forename: S
authors.initials: S
authors.lastname: Shak
authors.forename: E
authors.initials: E
authors.lastname: Puchelle
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D003371:Cough / Q000503:physiopathology; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000503:physiopathology*; D003850:Deoxyribonuclease I / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D009079:Mucociliary Clearance / Q000187:drug effects; D009093:Mucus / Q000187:drug effects*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012212:Rheology; D014783:Viscosity
chemical_list: D011994:Recombinant Proteins; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I